Jark Böttcher

发表

HUWE1 employs a giant substrate-binding ring to feed and regulate its HECT E3 domain

O. A. Petrova, R. Kurzbauer, D. Haselbach, 2021, Nature Chemical Biology.

HUWE 1 employs a giant substrate-binding ring to feed and regulate its HECT E 3 domain 1 2

O. A. Petrova, R. Kurzbauer, D. Haselbach, 2021 .

One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS.

P. Ettmayer, N. Kraut, M. Gmachl, 2021, Journal of medicinal chemistry.

Crystal Structure of the Werner’s Syndrome Helicase

Matthias Samwer, O. Gileadi, Simone Lieb, 2020, bioRxiv.

Pan-KRAS inhibitor disables oncogenic signalling and tumour growth

E. de Stanchina, Y. Pourfarjam, N. Kraut, 2023, Nature.

Target 2035 – an update on private sector contributions

T. Willson, S. Knapp, U. Lessel, 2023, RSC medicinal chemistry.

Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance

P. Ettmayer, S. Carotta, M. Kerenyi, 2020, Molecular Cancer Therapeutics.

Key factors for successful generation of protein-fragment structures requirement on protein, crystals, and technology.

S. Steinbacher, H. Steuber, R. Kiefersauer, 2011, Methods in enzymology.

Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRASG12C Inhibitor

A. Waterson, D. Rudolph, M. Gmachl, 2022, Journal of medicinal chemistry.

Donated chemical probes for open science

Anton Simeonov, Steve Hitchcock, Stefan Laufer, 2018, eLife.

Two solutions for the same problem: multiple binding modes of pyrrolidine-based HIV-1 protease inhibitors.

G. Klebe, A. Heine, A. Blum, 2011, Journal of molecular biology.

Structure of the helicase core of Werner helicase, a key target in microsatellite instability cancers

Matthias Samwer, O. Gileadi, Simone Lieb, 2020, Life Science Alliance.

Structure–kinetic relationship study of CDK8/CycC specific compounds

R. Huber, L. Neumann, E. Schneider, 2013, Proceedings of the National Academy of Sciences.

The structure of CDK8/CycC implicates specificity in the CDK/cyclin family and reveals interaction with a deep pocket binder.

R. Huber, L. Neumann, E. Schneider, 2011, Journal of molecular biology.

A Novel Antagonistic CD73 Antibody for Inhibition of the Immunosuppressive Adenosine Pathway

P. Nuciforo, Rachel Kroe-Barrett, J. Capdevila, 2021, Molecular Cancer Therapeutics.

Quinoline-based derivatives of pirinixic acid as dual PPAR alpha/gamma agonists.

M. Schubert-Zsilavecz, O. Rau, L. Popescu, 2007, Archiv der Pharmazie.

Structural and kinetic analysis of pyrrolidine-based inhibitors of the drug-resistant Ile84Val mutant of HIV-1 protease.

Gerhard Klebe, Wibke E Diederich, Jark Böttcher, 2008, Journal of molecular biology.

Targeting the Open‐Flap Conformation of HIV‐1 Protease with Pyrrolidine‐Based Inhibitors

G. Klebe, A. Heine, A. Blum, 2008, ChemMedChem.

Structure-guided design of C2-symmetric HIV-1 protease inhibitors based on a pyrrolidine scaffold.

Gerhard Klebe, Wibke E Diederich, Jark Böttcher, 2008, Journal of medicinal chemistry.

Synthesis of 2,3,4,7-tetrahydro-1H-azepines as privileged ligand scaffolds for the design of aspartic protease inhibitors via a ring-closing metathesis approach

Christof Gerlach, J. Böttcher, S. Brass, 2006 .

Unexpected Novel Binding Mode of Pyrrolidine‐Based Aspartyl Protease Inhibitors: Design, Synthesis and Crystal Structure in Complex with HIV Protease

G. Klebe, A. Heine, G. Müller, 2006, ChemMedChem.

An old target revisited: two new privileged skeletons and an unexpected binding mode for HIV-protease inhibitors.

Gerhard Klebe, Nils Griebenow, Jark Böttcher, 2005, Angewandte Chemie.

Hydroxyethylene sulfones as a new scaffold to address aspartic proteases: design, synthesis, and structural characterization.

G. Klebe, A. Heine, C. Sotriffer, 2005, Journal of medicinal chemistry.

Key factors for successful generation of protein-fragment structures requirement on protein, crystals, and technology.

S. Steinbacher, H. Steuber, R. Kiefersauer, 2011, Methods in enzymology.

The Potential of P1 Site Alterations in Peptidomimetic Protease Inhibitors as Suggested by Virtual Screening and Explored by the Use of CC‐Coupling Reagents

G. Klebe, C. Sotriffer, A. Evers, 2006, ChemMedChem.

Molecular basis of in vitro affinity maturation and functional evolution of a neutralizing anti-human GM-CSF antibody

M. Augustin, R. Ostendorp, J. Böttcher, 2016, mAbs.

Ligand 1 H NMR Chemical Shifts as Accurate Reporters for Protein-Ligand Binding Interfaces in Solution.

R. Konrat, P. A. Sánchez‐Murcia, L. Geist, 2023, Chemphyschem : a European journal of chemical physics and physical chemistry.

Synthesis, characterisation and natural abundance Os-187 NMR spectroscopy of hydride bridged triosmium clusters with chiral diphosphine ligands

J. Steed, A. Aliev, J. Böttcher, 2006 .

Fragment-based discovery of a chemical probe for the PWWP1 domain of NSD3

Julian E. Fuchs, O. Fedorov, C. Arrowsmith, 2019, Nature Chemical Biology.

Discovery of a Chemical Probe to Study Implications of BPTF Bromodomain Inhibition in Cellular and in vivo Experiments

Julian E. Fuchs, W. Sommergruber, K. Huber, 2023, ChemMedChem.

Inverse PI by NMR: Analysis of Ligand 1H-Chemical Shifts in the Protein-Bound State

Julian E. Fuchs, R. Konrat, J. Böttcher, 2021, bioRxiv.

Getting a Grip on the Undrugged: Targeting β‐Catenin with Fragment‐Based Methods

Julian E. Fuchs, M. Pearson, D. Breitsprecher, 2020, ChemMedChem.

Quinoline‐Based Derivatives of Pirinixic Acid as Dual PPAR α/γ Agonists

M. Schubert-Zsilavecz, O. Rau, L. Popescu, 2007 .